Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus.
The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.
Funding Rounds (5) - $153.44MUpdate
Current Team (7)Update
|May 10, 2016||SEC - UNITED STATES SECURITIES AND EXCHANGE COMMISSION|
|Feb 24, 2016||PRNewswire UK All - Otitis Media Market: Pipeline Review, Global API Manufacturers, 2016 Marketed and Phase III Drugs Landscape Reviewed in New Research Reports|
|Jan 29, 2016||Xconomy - West Coast Biotech Roundup: Gilead, Adicet, Otonomy, Fate & More|
|Jan 22, 2016||PRNewswire All - BNBuilders Taps Silicon Valley for San Diego's Biotech Growth|
|Jan 8, 2016||Xconomy - West Coast Bio Roundup: Big Waves, Big Cash & a Deep Pre-JPM16 Breath|
|Dec 11, 2015||UT San Diego - Otonomy's first drug approved|
|Nov 26, 2015||Business Wire - Research and Markets: Global Tinnitus Pipeline Review, H2 2015 - 9 Companies & 15 Drug profiles|
|Nov 22, 2015||San Diego Business Journal - Otonomy Enrolling Patients for Phase 3 Clinical Trial of Ménière’s Disease Treatment|
6275 Nancy Ridge Drive,
San Diego, CA 92121